Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
FDA Clears New ReWalk Product for Stroke Survivors
×
Error: Contact form not found.
by JNS.org
ReWalk Robotics Ltd.’s ReStore, an exoskeleton for stroke survivors. Photo: Screenshot.
JNS.org – The Food and Drug Administration has cleared a new product geared to help stroke survivors walk again.
Israel-based ReWalk Robotics Ltd. announced on Tuesday that its ReStore product will have a starting price in the United States of $28,900, though leasing options will be available.
Last week, ReStore received the CE mark, allowing it to be sold in the European Union.
ReWalk Robotics Ltd. is known for its exoskeleton that enables paraplegics to walk again. It received FDA clearance in 2014.
